Quest Diagnostics Incorporated

As of June 30, 2026, Quest Diagnostics Incorporated carries a market capitalization of 382.67B, placing it among publicly traded companies globally. Its enterprise value stands at 489.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Quest Diagnostics Incorporated's next confirmed earnings release is scheduled for February 4, 2027.

As of June 30, 2026, Quest Diagnostics Incorporated has 110.00M shares outstanding.

As of June 30, 2026, Quest Diagnostics Incorporated trades at a trailing price-to-earnings ratio of 20.81. The price-to-sales ratio is 1.91, and the price-to-book ratio stands at 2.91.

As of June 30, 2026, Quest Diagnostics Incorporated trades at an EV/EBITDA multiple of 12.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Quest Diagnostics Incorporated trades at an EV/FCF ratio of 13.29, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 489.94B versus a market cap of 382.67B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Quest Diagnostics Incorporated maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 80.81, indicating elevated leverage, while an interest coverage ratio of 8.22 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Quest Diagnostics Incorporated posted a return on equity (ROE) of 14.41, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.00 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.45, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.70, useful for judging operating efficiency across full business cycles. The company generates approximately 3.56M in revenue per employee across its workforce of 56,750.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 36.82 indicates how many times Quest Diagnostics Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Quest Diagnostics Incorporated recorded 5.59B in income tax expense. That works out to an effective tax rate of 22.79, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 24.53B, leaving 18.55B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 22, 2026, Quest Diagnostics Incorporated's stock has gained approximately 19.43% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Quest Diagnostics Incorporated generated 201.97B in revenue and converted that into 18.55B in net income, yielding earnings per share of 173.24. EBITDA reached 38.61B, while operating income came in at 28.57B.

As of June 30, 2026, Quest Diagnostics Incorporated holds 10.94B in cash and equivalents against 111.52B in total debt, resulting in a net debt position of 87.64B. Total book value stands at 131.32B, with working capital of 18.45B providing operational flexibility.

Quest Diagnostics Incorporated produced 33.25B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Quest Diagnostics Incorporated posted a gross margin of 33.11, reflecting its pricing power and cost economics. The operating margin of 14.14 and net profit margin of 9.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Quest Diagnostics Incorporated paid dividends of 57.14 per share. The dividend payout ratio of 31.19 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.51, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Quest Diagnostics Incorporated shareholders.

Quest Diagnostics Incorporated's most recent stock split took place on June 21, 2005 with a 1:2 split ratio.

As of June 30, 2026, Quest Diagnostics Incorporated has an Altman Z-Score of 6.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.